Home
Technology
Drug Delivery Platform
Sensitive DNA/RNA Synthesis Platform
Products & Services
COVID-19 Research Support
Liposomes Drug Delivery Services For COVID-19
COVID-19 mRNA Vaccine Development Services
Custom Oligo Synthesis Services For COVID-19 Research
DNA/RNA Synthesis Reagents
Common RNA Synthesis
Sensitive DNA/RNA Synthesis
Dyes Phosphoramidites
Labels Phosphoramidites
Linker Phosphoramidites
Oligo Analysis & Purification
siRNA
Custom siRNA
Chemically-Modified siRNA
Fluorescence-labeled siRNA
siRNA Control
siRNA Sets
Drug Delivery System
Exosome
Liposomes
GalNAc-siRNA Conjugates
Antibody-siRNA Conjugates
Peptide-siRNA conjugates
Polymer-siRNA Conjugates
Cholesterol-siRNA Conjugates
Nanoparticle-siRNA Conjugates
mRNA Vaccines
Support
News
mRNA-1647,the first infectious disease mRNA vaccine to enter the second phase of research
Onpattro, The First FDA-approved RNAi Drug
FDA approves first RNAi treatment for inherited rare diseases
Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of primary hyperoxaluria type 1 (PH1)
Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot for competition
Resources
Explore & Learn
FAQs
FAQs of siRNA
Ordering
About Us
Contact Us
Home
Products & Services
DNA/RNA Synthesis Reagents
Linker Phosphoramidites
Linker Phosphoramidites
Linker Phosphoramidites
*
Only for research. Not suitable for any diagnostic or therapeutic use.